Miltenyi Biomedicine Gmbh
Clinical trials sponsored by Miltenyi Biomedicine Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on tough blood cancers in early trial Results expected Sep 2026 (estimated)
- Personalized dosing may improve stem cell transplant survival in blood cancer patients Results expected Sep 2026 (estimated)
- Engineered immune cells take on tough lymphomas Results expected Dec 2026 (estimated)
- Engineered immune cells take on tough lymphoma in new trial Results expected Jan 2027 (estimated)